Product Description
CellMosaic has developed this kit for the site-specific conjugation of cysteine engineered IgG antibodies with Deruxtecan.
| Download Documents | |
|---|---|
| SDS | User Manual Supplied with Each Order |
Site-specific cysteine engineering is a well-established approach for controlling drug conjugation sites and producing highly homogeneous antibody-drug conjugates (ADCs) with a targeted drug-to-antibody ratio (DAR) of 1. The homogeneity of the final ADC depends on the uniformity of the engineered cysteine sites in the starting antibody.
The user supplies a single-cysteine (single-Cys) engineered IgG antibody, which may contain a blocked engineered cysteine through a mixed disulfide bond. The kit provides reagents to reduce the engineered cysteine and native interchain disulfide bonds, followed by controlled reoxidation to restore native disulfide bonds while leaving the engineered cysteine available for conjugation. The free cysteine thiol is then reacted with the supplied deruxtecan solution to produce a site-specifically conjugated ADC with a targeted DAR of 1.
This approach is based on the reduction and alkylation strategy described by Seattle Genetics (Sun et al., 2005, Bioconjugate Chemistry, 16, 1282–1290).
The resulting ADC is purified to remove unreacted drug and low-molecular-weight impurities. The kit components and protocols have been extensively validated through CellMosaic's custom bioconjugation services using various cysteine-engineered antibodies.
Note: The kit is also suitable for conjugating IgG antibodies engineered with two cysteine residues without modifying the protocol. However, this application has not been validated at CellMosaic due to the unavailability of such antibodies.
Standard Kit Configuration for CM11403 (Default: 1-3 mg per reaction, 1 Reaction included)
| Antibody Amount per Reaction | Number of Reactions per Kit | Catalog Number |
|---|---|---|
| 1–3 mg | 1 or 3 | CM11403x1 or CM11403x3 |
If you have any other customization needs, please provide the details above.
Drug Information
- Name: Deruxtecan (Mc-GGFG-DXd)
- Synonym: Exatecan derivative, DX 8951 derivative; DXd; payload for DS-8201a
- CAS number:1599440-13-7
- Chemical formula: C52H56FN9O13
- MW: 1034.0684
- Mechanism of action: Inhibition of topoisomerase I leads to inhibition of both DNA Replication and DNA transcriptions
Requirement for Antibody
- Single-Cys engineered antibody: the engineered cysteine typically exists in a blocked form through a mixed disulfide bond (e.g., glutathionylated cysteine) following antibody expression and purification.
- Preferably >90% pure by gel electrophoresis
- Total amount: 0.1 mg or 1-3 mg of protein content as measured by UV.
Key Features of this PerKit™
- Simple and efficient labeling of IgG with Deruxtecan, minimizing toxin exposure.
- Features enzymatic cleavable GGFG peptide linker.
- Enables site-specific conjugation at the eingineered cysteine (Cys) residue, targeting an average DAR of 1.
- Fast preparation: 8 hours total, with less than 4 hours of hands-on time.
- Includes all necessary reagents and supplies for preparation and purification.
- Post-conjugation services available at CellMosaic® for HPLC analysis and DAR determination.
Conjugation Chemistry

Protocol
Schematic workflow diagram for preparing single-cysteine antibody deruxtecan conjugates, starting with 3 mg of IgG. (Reagent volume will vary if the amount of IgG is less than 3 mg).

Frequently Asked Questions:
If you can’t find the answer you’re looking for or need information on general topics, please visit the main Frequently Asked Questions (FAQs) section.